CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-27 | Michaelson Jennifer See Remarks | Option exercise | +4,000 | $4.30 | $17K | 57,031 |
| 2022-09-27 | Michaelson Jennifer See Remarks | Sale | −4,000 | $12.40 | $50K | 53,031 |
| 2022-09-27 | Michaelson Jennifer See Remarks | Option exercise · Stock Option (Right to Buy) | −4,000 | 204,593 | ||
| 2022-08-15 | SUMER JACQUELYN L Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2022-08-08 | Michaelson Jennifer Chief Development Officer | Option exercise | +1,385 | $4.30 | $6K | 54,416 |
| 2022-08-08 | Michaelson Jennifer Chief Development Officer | Sale | −1,385 | $15.01 | $21K | 53,031 |
| 2022-08-08 | Michaelson Jennifer Chief Development Officer | Option exercise · Stock Option (Right to Buy) | −1,385 | 208,593 | ||
| 2022-08-04 | F2 Vision SCS 10% owner | Sale | −25,989 | $14.31 | $372K | 1,255,963 |
| 2022-08-03 | F2 Vision SCS 10% owner | Sale | −19,129 | $14.24 | $272K | 1,281,952 |
| 2022-08-02 | F2 Vision SCS 10% owner | Sale | −4,792 | $14.10 | $68K | 1,301,081 |
| 2022-07-25 | Michaelson Jennifer Chief Development Officer | Option exercise | +8,000 | $4.30 | $34K | 61,031 |
| 2022-07-25 | Michaelson Jennifer Chief Development Officer | Sale | −8,000 | $14.51 | $116K | 53,031 |
| 2022-07-25 | Michaelson Jennifer Chief Development Officer | Option exercise · Stock Option (Right to Buy) | −8,000 | 209,978 | ||
| 2022-07-19 | Savill Corrine Acting Chief Business Officer | Sale | −14,958 | $15.22 | $228K | 149,615 |
| 2022-07-18 | Savill Corrine Acting Chief Business Officer | Sale | −5,042 | $15.06 | $76K | 164,573 |
| 2022-07-11 | Savill Corrine Acting Chief Business Officer | Sale | −39,800 | $13.33 | $531K | 169,815 |
| 2022-07-11 | Savill Corrine Acting Chief Business Officer | Sale | −200 | $13.85 | $3K | 169,615 |
| 2022-06-30 | Michaelson Jennifer Chief Development Officer | Grant or award | +1,620 | $10.90 | $18K | 53,031 |
| 2022-06-30 | Trigilio Jeffrey Chief Financial Officer | Grant or award | +1,451 | $10.90 | $16K | 41,201 |
| 2022-06-30 | AHMED NADIM President and CEO | Grant or award | +1,620 | $10.90 | $18K | 9,710 |
Page 12 of 23 · 446 trades